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Ganciclovir therapy in cytomegalovirus (CMV) infection 
in immunocompetent pediatric patients 
Maria L. Avila-Agiiero, (k2) Maria M. Paris,(1,3) Wilberth Alfaro,@) Claudio R. Avila-Agiiero(4) 
and Idis Faingezicht(1,2) 
Objectives: To evaluate the outcome of immunocompetent pediatric patients who had positive cytomegalovirus 
(CMV) antigenemia and received ganciclovir. 
Methods: A retrospective review was done of patients who had a CMV infection based on positive antigenemia. 
Medical charts were reviewed for the following information: age, sex, underlying disease, symptoms and signs, 
laboratory results, complementary diagnostic procedures, duration and dose of ganciclovir therapy, concomitant 
medications, complications, and outcome. 
Results: Sixty-four patients with positive CMV antigenemia were identified; 15 patients were excluded from the study 
because of their underlying diseases. Of the remaining 49 patients, 26 (53%) were female; the median age was 11.5 
months (range 0.3-132 months). Sixty-one percent (30/49) of these patients received ganciclovir (5-10 mg/kg/day) 
for a median of 14 days (range 7-42 days). Clinical findings included: fever, anemia, hepatomegaly, failure to thrive, 
elevated liver enzymes, splenomegaly, seizures, and thrombocytopenia. Sixty-three percent (19/30) of the treated 
patients had negative antigenemia at the end of therapy. CMV antigenemia remained positive in six (20%) patients. 
Nine patients received a second course of ganciclovir. 
Conclusions: Ganciclovir was effective in 80% of patients, as determined by negative antigenemia at the end of therapy. 
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INTRODUCTION 
Cytomegalovirus (CMV) infection is a common disease 
worldwide. It is estimated that about 40-100% of adults 
have been infected with CMV during the last four 
decades.1,2 CMV infection is a major cause of mental 
retardation and congenital deafness, and it is also respon- 
sible for a great deal of disease in immunocompromised 
patients.3 
Because of the long period of latent infection and 
wide range of CMV disease presentations, epidemio- 
logic and medical understanding has come slowly. Our 
understanding of this infection has increased due to the 
clinical events occurring in iatrogenic immunosuppres- 
sion in patients receiving immunosuppressive treatment 
and in HIV-infected patients.4 
Although CMV infection can be fatal in immuno- 
compromised patients, in immunocompetent patients 
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this infection is usually asymptomatic, and is character- 
ized by malaise, fever, mild liver enzyme elevations, and 
lymphocytosis. There have been reports of immuno- 
competent people, mainly adult patients, severely 
affected by CMV5 
Even though the outcome of CMV infection has 
improved since ganciclovir has been available for 
immunocompromised patients with CMV retinitis or 
gastrointestinal disease, little information is available 
with regard to the advantage of ganciclovir therapy in 
severe CMV disease in immunocompetent patients.6 
Recently, antigenemia was introduced as a helpful 
diagnostic procedure to evaluate patients with CMV 
infection. However, the usefulness of this diagnostic test 
in the management of CMV infection in immuno- 
competent patients is not clear.7 
Because of an increase in the number of cases 
presenting with clinical signs and symptoms of CMV 
infection with positive antigenemia, we sought to assess 
the outcome of immunocompetent patients with posi- 
tive CMV antigenemia, whether ganciclovir treated or 
not, and the usefulness of CMV antigenemia in the 
management of these patients. 
METHODS AND MATERIALS 
This is a retrospective review of patients hospitalized at 
the National Children’s Hospital, who were diagnosed 
with CMV infection based on positive antigenemia. 
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Patients were identified by a positive antigenemia result 
from the laboratory records. 
Medical charts were reviewed for the following 
information: age, sex, underlying disease, symptoms and 
signs, laboratory results, complementary diagnostic 
procedures, duration and dose of ganciclovir therapy, 
concomitant medications, complications, and outcome. 
The antigenemia test used in our hospital is based 
on the immunocytochemical detection of CMV immedi- 
ate early antigens (~~65) in blood leukocytes. The 
interpretation of the test was as follows: mild positive 
antigenemia, l-10/200 000 leukocytes positive; moderate 
positive antigenemia, lo-49/200 000 leukocytes positive; 
strongly positive antigenemia, >50/200 000 leukocytes 
positive. 
For this review, patients with HIV infection, solid 
organ transplantation or bone marrow transplantation 
were excluded. Additionally, patients who had negative 
CMV antigenemia, regardless of a clinical presentation 
compatible with a CMV infection, were also excluded. 
RESULTS 
Sixty-four patients have had a positive antigenemia result 
since this test was introduced in our hospital in 1993. 
Fifteen patients (23%) were excluded from this analysis 
because of their underlying diseases: HIV, six patients; 
renal transplant, four patients; heart-lung transplant and 
bone marrow transplant, one and four patients, 
respectively. Of the remaining 49 patients, 26 (53%) 
were female. The median age was 11.5 months (range 
0.3-132 months). 
Seven patients (14%) were considered to have 
congenital CMV infection: positive antigenemia at I1 
month of age, and no history of blood transfusion. Even 
though eight patients (16%) had a history of previous 
blood transfusion, none of them had an antigenemia test 
performed before the transfusion. The remaining 34 
patients (70%) had no previous medical history of blood 
product transfusion, and their antigenemia was deter- 
Table 1. Clinical and laboratory findings in children with CMV 
disease and positive antigenemia 
Clinical finding” Total 
n=49 
% 
Fever 
Anemia 
Hepatomegaly 
Failure to thrive 
Pneumonitis 
Increase in liver function 
abnormalities 
Jaundice 
Splenomegaly 
Seizures 
Purpura 
Thrombocytopenia 
Petechiae 
49 
49 
40 
25 
20 
15 
15 
10 
10 
10 
10 
10 
100 
100 
82 
51 
41 
31 
31 
20 
20 
20 
20 
20 
aThirty-five of 49 (71%) patients had 23 clinical findings 
mined by at least 3 months of age. Table 1 shows the 
main clinical and laboratory findings for these patients. 
Of the seven (7/49, 14%) patients who died, four had 
CMV congenital infection, four had chronic encephalitis, 
and one had a hemophagocytic syndrome. 
Thirty (30/49, 61%) patients received intravenous 
ganciclovir (5-10 mg/kg/day) for a median of 14 days 
(range 7-42 days). None of the patients received oral 
ganciclovir. There were no reports of adverse events 
associated with ganciclovir therapy in these patients. Of 
the 30 patients who were treated, 25 (83%) had strongly 
positive antigenemia, and five (17%) had moderate 
positive antigenemia. Sixty-three percent (19/30) of 
treated patients had negative antigenemia at the end of 
therapy. On the other hand, CMV antigenemia remained 
moderately positive in 6/30 (20%) patients, despite 
clinical improvement and lack of clinical findings at the 
end of therapy (Table 2). Five (17%) patients received 
a second course of ganciclovir therapy due to persistent 
positive antigenemia. Furthermore, four ganciclovir- 
treated patients who had negative antigenemia at the 
end of therapy relapsed within 8 weeks, showing strongly 
positive antigenemia and clinical findings compatible 
with CMV infection. These nine patients received a 
second course of ganciclovir, and had negative anti- 
genemia by the end of therapy. 
However, ganciclovir was effective in SO%, as deter- 
mined by negative antigenemia at the end of therapy. 
Of the 19 (35%) patients who did not receive ganci- 
clovir, four died with persistent positive antigenemia, 
and seven had negative antigenemia 2 weeks after the 
first positive antigenemia. All of these patients had mild 
positive antigenemia (Table 3). The remaining eight 
patients did not have more tests performed and 
remained asymptomatic. 
Table 2. Post-treatment antigenemia in patients who received 
ganciclovir 
Antigenemia Positive Negative 
n=6 n=24 
Strongly positive 5a 20 
Moderately positive 1 4 
Mildly positive 0 0 
“These patients received a second course of therapy. 
Total 
n=30 
25 
5 
0 
Table 3. Antigenemia results in non-ganciclovir-treated 
patients 
Antigenemia Initial Control 
n=19 n=ll 
Positive Negative 
Strongly positive 4 4 0 
Moderately positive 7 0 7 
Mildly positive 8a 
aNo more antigenemia tests were performed for these patients, and 
they remained asymptomatic. 
280 International Journal of Infectious Diseases I Volume 7, Number 42003 
Extensive immunologic evaluation (lymphocyte 
subset enumeration, in vitro lymphocyte studies, and 
serum immunoglobulin) was performed in 42/49 (86%) 
patients, and none showed any evidence of immuno- 
deficiency disease. Other infections, such as human 
immunodeficiency virus, Epstein-Barr virus and other 
bacterial diseases, were excluded in the differential 
diagnosis. 
DISCUSSION 
Human CMV is the most common cause of congenital 
and perinatal infections throughout the world, and 
probably the most important infective cause of mental 
retardation and non-hereditary sensory deafness in 
children.1-3 A high prevalence of CMV infection is 
associated mainly with universal breastfeeding practices 
rather than with crowding or poverty.8,9 Perinatal CMV 
infection usually follows a benign course in immuno- 
competent individuals, but the virus remains latent or 
persistent in the host cells thereafter.6-9 
A clinical diagnosis of CMV infection is generally 
difficult, and rapid and accurate laboratory diagnosis is 
necessary for appropriate patient management. 
New techniques have greatly increased the sensi- 
tivity and specificity of CMV diagnosis. Serologic assays 
such as enzyme immunoassays and latex agglutination 
assays are accurate and efficient for screening donors 
and recipients and for determining susceptibility to 
primary CMV infection.8 
The presence and quantity of virus and viral pro- 
teins in peripheral blood leukocytes is a new direct 
method for diagnosing active CMV infection, and is an 
effective indicator of severity of infection.7,9 Active 
CMV infection can be diagnosed by detecting positive 
CMV antigenemia, which has a sensitivity and specificity 
of 290%, increasing to 100% in symptomatic patients.7 
On average, this test provides diagnostic inform- 
ation at least 1 week earlier than other established 
methods. Moreover, the level of CMV antigenemia has 
been related to the severity of disease. The finding of 
CMV in white blood cells indicates active viral replic- 
ation in the body.9 Here, we used CMV antigenemia as 
a marker of disease, and found a close relationship 
between strongly positive antigenemia and severe 
disease. All non-treated patients had mild positive 
antigenemia. Patients who relapsed had strongly 
positive antigenemia before ganciclovir therapy. These 
findings could indicate the emergence of ganciclovir- 
resistant CMV, but the definition is dependent on the 
demonstration of reduced susceptibility of CMV isolates 
to ganciclovir in vitro (typically, an ICSO > 6 yM) by use 
of a plaque reduction assay, and this is a condition 
observed predominantly among organ transplant 
recipients, particularly recipients of kidney, pancreas and 
lung transplants.lO Because this is a retrospective study, 
information regarding long-term follow-up (1-2 years) 
is not available to evaluate whether resistance emerged 
after treatment. Furthermore, determination of CMV 
susceptibility to ganciclovir is not done in our hospital 
at this time. Based on the above limitations, it is possible 
that CMV antigenemia could be used as a marker to 
monitor disease progression and its response to specific 
chemotherapy. 
The efficacy of ganciclovir therapy in children with 
CMV infection remains controversial. Ganciclovir, a 
guanosine analog, selectively inhibits CMV DNA 
polymerase, and is the antiviral used to treat immuno- 
compromised patients such as transplant recipients and 
AIDS patients with active CMV infection. Similar to 
reports from Gudnason et al,ll ganciclovir was well 
tolerated in this study. Here, we did not find toxicity to 
be associated with ganciclovir therapy. These results 
contrast with those reported in adults, where toxicity 
manifested by myelosuppression, hepatocellular dysfunc- 
tion, thrombocytopenia, infusion site reactions, gastro- 
intestinal abnormalities and central nervous system 
abnormalities is frequently reported. In patients with 
reproductive potential, the most worrying risks are those 
of permanent infertility and of teratogenesis.6J2J3 
Although few data on the use of ganciclovir in 
pediatric immunocompetent patients exist,14 in this 
report an improvement manifested by reduction or 
resolution of clinical symptoms and negative anti- 
genemia was observed in 80% of treated patients. 
Previously, Eddleston et ali5 reviewed 34 immuno- 
competent adult patients with CMV infection. Of these 
34 patients, 15 died (including three treated patients), 
and only 12 patients received antiviral therapy 
(ganciclovir, 6; vidarabine, 3; acyclovir, 2; and foscarnet, 
1). Here, four patients who received ganciclovir therapy 
died; however, these patients had congenital CMV 
infection. Furthermore, other investigators reported 
immunocompetent children who had received ganci- 
clovir therapy, and in these cases, ganciclovir treatment 
might have resulted in a survival advantage.16-l9 
However, because these are recent reports, other factors 
related to advances in medical care may account for the 
improvement and change in survival outcome. 
Recently, Kimberlin et alzO presented the results of 
a randomized controlled trial involving 100 newborns 
who had symptomatic congenital CMV infection 
involving the central nervous system; they concluded 
that ganciclovir therapy might protect against hearing 
deterioration. 
In summary, a high-quality clinical trial must be 
performed to assess the efficacy and safety of ganciclovir 
therapy in immunocompetent patients with severe CMV 
disease. The expected beneficial effect of the ganciclovir 
treatment must be balanced against the potential for side 
effects. Severe CMV infection may prove fatal. Therefore, 
we believe that early administration of ganciclovir must 
be considered in patients with CMV disease as soon as 
the severe nature of the infection is defined. Furthermore, 
more studies are necessary to confirm these results and 
assess the role of CMV antigenemia as a diagnostic and 
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outcome tool in the treatment of CMV disease in 
immunocompetent patients. 
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